Q-omics provides the consensus-scored ELP5 profile across patient tissues and cancer cell-line models. ELP5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ELP5 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ELP5 RNA expression shows 19,016 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ELP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELP5 survival associations across molecular data types. ELP5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELP5 RNA expression–survival associations across cancer types. High ELP5 expression shows unfavorable associations in ACC, KICH, LIHC, MESO and KIRC, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ELP5 RNA expression.
This table summarizes ELP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ELP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELP5 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in HNSC, LIHC and KIRC. The HNSC box plot shows higher ELP5 RNA expression in tumor versus normal tissue (log2 FC = +0.568, t-test p < 0.001).
This table shows molecular features associated with ELP5 in patient tissues and cancer cell lines. In patient samples, ELP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ELP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
